As our understanding of the pathogenesis of cancers grows and new treatment modalities become available, so too does the number of key research questions in oncology that need answering. Frontiers in Oncology is working with members of our Editorial Board to tackle some of these key questions through Editor’s Challenges, each of which pose a key question in the oncology field.
We are delighted to present this Editor’s Challenge, led by Dr. Luciano Mutti, and in collaboration with Dr. Steven Gray, asking what the true impact on patient survival of ICIs in thoracic cancer treatment.
The Impact of Immune Checkpoint Inhibitors (ICIs) on Survival in Treatment of Thoracic Malignancies Since the early 2000s, new treatment strategies for thoracic malignancies have emerged, including immune checkpoint inhibitors (ICIs). Despite improved treatment options, thoracic malignancies still have poor prognoses. Lung cancer has the lowest 5-year survival rate compared to other cancer sites and standard treatments with cytotoxic anticancer drugs have limited therapeutic effects. Multiple factors influence this, including cigarette smoking, sociodemographic factors, abnormal progression of the disease such as metastasis, and resistance to currently available anticancer therapies.
In recent years, as the understanding of the mechanisms of tumor immunotherapy has increased, and anti-PD-1 antibodies, one of the immune checkpoint inhibitors, have shown positive results in clinical trial, the treatment of thoracic cancers have entered a new era. However, responses to ICIs are clinically scattered, and the prognostic factors are still not well defined. Further research is vital to understand the true impact of ICIs on survival in the treatment of thoracic malignancies.
This Research Topic welcomes Original Research and Review Articles that focus on expanding our understanding of survival in thoracic cancer patients treated with ICIs.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Other collections in our Editor's Challenge series:
Editor's Challenge: Claudio Cerchione - Is it Time for a Targeted Therapy in Multiple Myeloma? Editor's Challenge: Abhishek Mahajan - How Can Precision Oncology be Advanced with Validated Imaging-Based Nomograms? Editor's Challenge: Mohamed Rahouma - How Can We Optimize the Management and Treatment of Cardiac Tumors and Cardiac Complications of Cancer? Editor's Challenge: Walter Storkus - Sexual Dimorphism and the Host Immune Response to Renal Cell Carcinoma Editor's Challenge: Dr. Qingxin Mu - How can Nanomedicine Approaches Advance Multi-targeting Strategy in Combination Cancer Therapy?As our understanding of the pathogenesis of cancers grows and new treatment modalities become available, so too does the number of key research questions in oncology that need answering. Frontiers in Oncology is working with members of our Editorial Board to tackle some of these key questions through Editor’s Challenges, each of which pose a key question in the oncology field.
We are delighted to present this Editor’s Challenge, led by Dr. Luciano Mutti, and in collaboration with Dr. Steven Gray, asking what the true impact on patient survival of ICIs in thoracic cancer treatment.
The Impact of Immune Checkpoint Inhibitors (ICIs) on Survival in Treatment of Thoracic Malignancies Since the early 2000s, new treatment strategies for thoracic malignancies have emerged, including immune checkpoint inhibitors (ICIs). Despite improved treatment options, thoracic malignancies still have poor prognoses. Lung cancer has the lowest 5-year survival rate compared to other cancer sites and standard treatments with cytotoxic anticancer drugs have limited therapeutic effects. Multiple factors influence this, including cigarette smoking, sociodemographic factors, abnormal progression of the disease such as metastasis, and resistance to currently available anticancer therapies.
In recent years, as the understanding of the mechanisms of tumor immunotherapy has increased, and anti-PD-1 antibodies, one of the immune checkpoint inhibitors, have shown positive results in clinical trial, the treatment of thoracic cancers have entered a new era. However, responses to ICIs are clinically scattered, and the prognostic factors are still not well defined. Further research is vital to understand the true impact of ICIs on survival in the treatment of thoracic malignancies.
This Research Topic welcomes Original Research and Review Articles that focus on expanding our understanding of survival in thoracic cancer patients treated with ICIs.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Other collections in our Editor's Challenge series:
Editor's Challenge: Claudio Cerchione - Is it Time for a Targeted Therapy in Multiple Myeloma? Editor's Challenge: Abhishek Mahajan - How Can Precision Oncology be Advanced with Validated Imaging-Based Nomograms? Editor's Challenge: Mohamed Rahouma - How Can We Optimize the Management and Treatment of Cardiac Tumors and Cardiac Complications of Cancer? Editor's Challenge: Walter Storkus - Sexual Dimorphism and the Host Immune Response to Renal Cell Carcinoma Editor's Challenge: Dr. Qingxin Mu - How can Nanomedicine Approaches Advance Multi-targeting Strategy in Combination Cancer Therapy?